Because EVs originating from individual tumour cells display the same tumour antigen specific for that tumour, providing such tumor-specific EVs can activate dendritic cells (DCs), which can then activate CD8 + T cells’ antitumor potential [87]. This evidence concerns the gene CD8A and neoplasm.